Drug delivery in a tumour cord model: a computational simulation.
暂无分享,去创建一个
M. E. Hubbard | M. Hubbard | P. Loadman | S. Smye | R. Phillips | M. Jové | C. Twelves | M. Jove | P. M. Loadman | R. M. Phillips | C. J. Twelves | S. W. Smye
[1] Levkovich YuI,et al. Blood flow velocity in capillaries of brain and muscles and its physiological significance. , 1981, Microvascular research.
[2] M D'Incalci,et al. Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity , 2014, Clinical pharmacology and therapeutics.
[3] J. Double,et al. A critical appraisal of the predictive value of in vitro chemosensitivity assays. , 1990, Journal of the National Cancer Institute.
[4] B Hoerni,et al. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. , 1982, European journal of cancer & clinical oncology.
[5] Lothar Lilge,et al. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.
[6] S. Piscitelli,et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer , 1993, Clinical pharmacology and therapeutics.
[7] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[8] Spring Berman,et al. A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. , 2013, Nano today.
[9] T. Secomb,et al. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. , 2000, Neoplasia.
[10] S W Smye,et al. A mathematical model of doxorubicin penetration through multicellular layers. , 2009, Journal of theoretical biology.
[11] M. Hiraoka,et al. Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. , 2008, Biochemical and biophysical research communications.
[12] G. Hortobagyi,et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma , 1989, Cancer.
[13] C. Haanen,et al. Clinical Pharmacokinetics of Doxorubicin , 1988, Clinical pharmacokinetics.
[14] J. Jenkins,et al. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. , 1983, Cancer research.
[15] Ian F Tannock,et al. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] L. Mawdesley-Thomas. Research into Fish Diseases , 1972, Nature.
[17] Abdel Kareem Azab,et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.
[18] S. Eikenberry. Theoretical Biology and Medical Modelling Open Access a Tumor Cord Model for Doxorubicin Delivery and Dose Optimization in Solid Tumors , 2022 .
[19] Nicolas André,et al. Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.
[20] Philipp M. Altrock,et al. The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.
[21] E. Rofstad,et al. Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast‐enhanced MRI , 2007, Journal of magnetic resonance imaging : JMRI.
[22] T. Waldman,et al. PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells , 2004, Cancer Research.
[23] W. Pigram,et al. Stereochemistry of intercalation: interaction of daunomycin with DNA. , 1972, Nature: New biology.
[24] E. D. Bal de Kier Joffé,et al. Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids , 2015, PloS one.
[25] J. Moore,et al. Tumour cords in 52 human bronchial and cervical squamous cell carcinomas: inferences for their cellular kinetics and radiobiology. , 1985, British Journal of Cancer.
[26] Ralph Weissleder,et al. A Systems Approach for Tumor Pharmacokinetics , 2011, PloS one.
[27] S. Wallace,et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.
[28] B. Desoize,et al. Cell culture as spheroids: an approach to multicellular resistance. , 1998, Anticancer research.
[29] Q. Yao,et al. Overcoming drug resistance in pancreatic cancer , 2011, Expert opinion on therapeutic targets.
[30] Y. Oda,et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models , 2014, Cancer science.
[31] B. Waclaw,et al. Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. , 2012, Physical review letters.
[32] Ivanov Kp,et al. Blood flow velocity in capillaries of brain and muscles and its physiological significance , 1981 .
[33] T. Secomb,et al. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.
[34] R M Phillips,et al. Mathematical and computational models of drug transport in tumours , 2014, Journal of The Royal Society Interface.
[35] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[36] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[37] M. Zucchetti,et al. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response , 2015, Molecular Cancer Therapeutics.